Clinical Trial

Empagliflozin Reversal of Arterial StiffnEss in Aging

Study acronym: ERASE-Aging
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-07-11; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2024-09-19
Trial Details
NCT Number NCT06506422
Lead Sponsor University of Missouri-Columbia
Conditions Aging, Arterial Stiffness
Enrollment 80 participants
Start Date 2024-08-18
Primary Completion 2028-10-31 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-06